Buoyed by optimism over the label expansion of Amarin’s (AMRN) flagship drug, Vascepa, the fish oil drug maker’s stock has run off to the races — up over 60% year-to-date. But how long can that last? This afternoon, US investment giant Oppenheimer predicted an imminent crash in Amarin shares.Oppenheimer analyst Leland Gershell and his team joined a small, but vocal camp of bearish folks waving investors away from Amarin stock. Gershell initiated coverage on AMRN with an “underperform” rating and a $7.00 price target, predicting the stock will drop about 70% in the next 12 months. (To watch Gershell’s track …read more
Source:: Yahoo Finance
